Flavonoids as modulators of gut-liver axis: emerging therapeutic strategies for MAFLD
Frontiers in Pharmacology · 16.10.2025 · 16
DOI: 10.3389/fphar.2025.1657751 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 16.10.2025. Verfasst von Mengxuan Hao und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, China-Singapore B…. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 219 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a significant global health challenge affecting approximately 25% of adults worldwide. Given the limited efficacy of existing therapies, there is an urgent need for novel treatment strategies. Flavonoids, a diverse class of natural polyphenolic compounds, exhibit significant potential in ameliorating MAFLD by modulating hepatic lipid metabolism and immune-inflammatory responses via gut-liver axis. This review systematically explores the interactions between flavonoids and gut microbiota, elucidating their role in MAFLD progression. We highlight how flavonoid structural diversity and microbial biotransformation modulate multiple key pathways, such as PPARα, PPARγ, ERβ, Nrf2, NF-κB, and FXR signalling. These multi-target mechanisms underpin the therapeutic potential of flavonoids in reducing lipid accumulation, oxidative stress, inflammation, and fibrosis in MAFLD. We also discuss innovative strategies, including flavonoid-probiotic synergies, nanotechnology-enhanced delivery systems, and personalized nutrition strategies. By integrating evidence from preclinical models and clinical trials, we highlight the translational potential of flavonoid-based interventions for MAFLD management. Our analysis underscores flavonoids as multi-target, safe and effective solutions for MAFLD management, warranting further clinical studies to translate these findings into routine clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, China-Singapore Belt and Road Joint Laboratory on Infection Research and Drug Developme…
- Yuhang Institute of Medical Science Innovation and Transformation, Hangzhou, China.
- Key Laboratory of Oral Biomedical Research of Zhejiang Province, Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, Cance…
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
- Jinan Microecological Biomedicine Shandong Laboratory, Jinan, China.
- College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Zitieren
APA
Hao, M., Wang, Z., Wang, L., Yimamu, A., Su, X., Zhang, M., Li, X., Zhang, Q., & Sun, Z. (2025). Flavonoids as modulators of gut-liver axis: emerging therapeutic strategies for MAFLD. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1657751
Vancouver
Hao M, Wang Z, Wang L, Yimamu A, Su X, Zhang M, et al. Flavonoids as modulators of gut-liver axis: emerging therapeutic strategies for MAFLD. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1657751
BibTeX
@article{Hao2025,
author = {Hao, Mengxuan and Wang, Zihui and Wang, Liren and Yimamu, Aidiya and Su, Xiaoling and Zhang, Minmin and Li, Xincan and Zhang, Quanlong and Sun, Zeyu},
title = {Flavonoids as modulators of gut-liver axis: emerging therapeutic strategies for MAFLD},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1657751}
}
EUVIMED